Alzinova’s lead candidate, ALZ-101, is a unique and highly specific therapeutic vaccine generated using proprietary AβCC peptide™ technology. ALZ-101 is an Aβ 1–42 oligomer mimic, and its use as an active immunotherapy agent is intended to elicit a strong immune reaction against the ...